Recombinant antibody fragments.

Recombinant antibodies and their fragments now represent over 30% of all biological proteins undergoing clinical trials, which recently culminated in FDA approval for the first engineered cancer therapeutic antibody. Other successful applications include both the effective enhancement of the human immune response for cancer therapy and the reduction of unwanted immune rejections following transplantation and antibody therapy. Important advances have been made in the methods for design, selection and production of these new types of engineered antibodies. Innovative selection methods have enabled the isolation of catalytic antibodies and high-affinity viral-specific antibodies, the latter capable of redirecting viruses for gene therapy applications. In numerous practical applications, recombinant antibody fragments have been fused to radioisotopes, drugs, toxins, enzymes and biosensor surfaces.

[1]  Frances H. Arnold,et al.  Molecular evolution by staggered extension process (StEP) in vitro recombination , 1998, Nature Biotechnology.

[2]  R. Dornburg,et al.  Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies , 1997, Journal of virology.

[3]  M Aizawa,et al.  A fluoroimmunoassay based on immunoliposomes containing genetically engineered lipid-tagged antibody. , 1997, Analytical chemistry.

[4]  K. Roux,et al.  Flexibility of human IgG subclasses. , 1997, Journal of immunology.

[5]  N. Siemers,et al.  Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. , 1997, Bioconjugate chemistry.

[6]  H. Lester,et al.  Inhibition of an inwardly rectifying K+ channel by G-protein α-subunits , 1996, Nature.

[7]  P. Iliades,et al.  Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.

[8]  I. Pastan,et al.  Targeted therapy of cancer with recombinant immunotoxins. , 1997, Biochimica et biophysica acta.

[9]  D. Shakes,et al.  Expression patterns and transcript processing of ftt-1 and ftt-2, two C. elegans 14-3-3 homologues. , 1997, Journal of molecular biology.

[10]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[11]  O. Burrone,et al.  Mammalian cell expression of dimeric small immune proteins (SIP). , 1997, Protein engineering.

[12]  J. L. Casey,et al.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. , 1996, British Journal of Cancer.

[13]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial , 1997, Cancer Chemotherapy and Pharmacology.

[14]  A. Kortt,et al.  Effects of substitutions in the binding surface of an antibody on antigen affinity. , 1998, Protein engineering.

[15]  A. Plückthun,et al.  Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology , 1997, FEBS letters.

[16]  R. Kontermann,et al.  Complement recruitment using bispecific diabodies , 1997, Nature Biotechnology.

[17]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[18]  G. Sheldrick,et al.  X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain. , 1997, Folding & design.

[19]  A. Kaufmann,et al.  Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked immunosorbent assay. , 1997, Analytical biochemistry.

[20]  W. Marasco,et al.  Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. , 1997, Annual review of microbiology.

[21]  Larry L. Green,et al.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.

[22]  E. Vitetta,et al.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Tsumoto,et al.  Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen. , 1997, Protein engineering.

[24]  A. Malmborg,et al.  Selective phage infection mediated by epitope expression on F pilus. , 1997, Journal of molecular biology.

[25]  Z. Eshhar.  Tumor-specific T-bodies: towards clinical application , 1997, Cancer Immunology, Immunotherapy.

[26]  M. Little,et al.  Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. , 1997, Protein engineering.

[27]  J. Wells,et al.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.

[28]  S. Deutscher,et al.  Site-specific Mutagenesis of a Recombinant Anti-single-stranded DNA Fab , 1997, The Journal of Biological Chemistry.

[29]  E. Hewat,et al.  Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. , 1997, Journal of molecular biology.

[30]  L. Nieba,et al.  Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. , 1997, Protein engineering.

[31]  D. Allen,et al.  Enzyme immunoassays using bispecific diabodies. , 1997, Immunotechnology : an international journal of immunological engineering.

[32]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[33]  C. Barbas,et al.  Phage display of combinatorial antibody libraries. , 1997, Current opinion in biotechnology.

[34]  A Heine,et al.  Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. , 1997, Science.

[35]  A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein. , 1997, Blood.

[36]  M. Mack,et al.  Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer , 1997, Cancer Immunology, Immunotherapy.

[37]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Pastan,et al.  Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation. , 1997, Journal of molecular biology.

[39]  G. Winter,et al.  Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. , 1997, Protein engineering.

[40]  A. McCoy,et al.  Electrostatic complementarity at protein/protein interfaces. , 1997, Journal of molecular biology.

[41]  I. Kovesdi,et al.  Targeted adenovirus-mediated gene delivery to T cells via CD3 , 1997, Journal of virology.

[42]  D. Newton,et al.  Cloning and cytotoxicity of a human pancreatic RNase immunofusion. , 1997, Immunotechnology : an international journal of immunological engineering.

[43]  A. Garen,et al.  Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Vitetta,et al.  Immunotoxins for the Treatment of B-Cell Lymphomas , 1997, Molecular medicine.

[45]  L. Presta,et al.  Antibody Humanization Using Monovalent Phage Display* , 1997, The Journal of Biological Chemistry.

[46]  R. Webster,et al.  Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. , 1997, Protein engineering.

[47]  G. Adams,et al.  Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.

[48]  P. Hudson,et al.  Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. , 1997, Gene.

[49]  P. Carter,et al.  Engineering antibodies for imaging and therapy. , 1997, Current opinion in biotechnology.

[50]  P. Iliades,et al.  Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments , 1998, FEBS letters.

[51]  A. George,et al.  Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. , 1997, Journal of immunological methods.

[52]  G. Adams,et al.  Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.

[53]  K. Larsson,et al.  Identification of Framework Residues in a Secreted Recombinant Antibody Fragment That Control Production Level and Localization inEscherichia coli * , 1997, The Journal of Biological Chemistry.

[54]  S. Morrison,et al.  Antibody-IL-2 fusion proteins: a novel strategy for immune protection. , 1997, Human antibodies.

[55]  H R Hoogenboom,et al.  Antibody phage display technology and its applications. , 1998, Immunotechnology : an international journal of immunological engineering.

[56]  A. Murzin,et al.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Hawkins,et al.  The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.

[58]  A. Cattaneo,et al.  Inhibition of murine leukaemia virus retrotranscription by the intracellular expression of a phage-derived anti-reverse transcriptase antibody fragment. , 1997, The Journal of general virology.

[59]  R C Stevens,et al.  Structural insights into the evolution of an antibody combining site. , 1997, Science.

[60]  G. Winter,et al.  Retargeting serum immunoglobulin with bispecific diabodies , 1997, Nature Biotechnology.

[61]  H. Hoogenboom,et al.  Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNFα monoclonal antibodies , 1997 .

[62]  P. Colman,et al.  Structure of antibody-antigen complexes: implications for immune recognition. , 1988, Advances in immunology.